Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study

Gynecologic Oncology Reports(2024)10.1016/j.gore.2024.101475Source: DataRank Database

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study is a research paper published in Gynecologic Oncology Reports (2024). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.40)OA: goldTopics (21)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Roberto Angeli Morales,Alicja Kamińska ORCID,Gerardo Colón‐Otero ORCID,Swapna Kochuveettil

Live enrichment

PubMed:39206109 OpenAlex:https://openalex.org/W4401304660

Nihon Kohden America

Grant: UL1 TR002377

National Cancer Institute

Grant: CA15083

National Institutes of Health

Grant: 3P30CA015083-37S2

Mayo Comprehensive Cancer Center Grant

National Institutes of Health

Grant: 3UL1TR002377-04S5

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Regan Theiler)

NCI NIH HHS

Grant: N01 CA015083

NCI NIH HHS

Grant: P30 CA015083

FWCI

0.40

Citation Percentile

0.7%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.gore.2024.101475

publisherhttps://doi.org/10.1016/j.gore.2024.101475

publisherhttps://api.elsevier.com/content/article/PII:S2352578924001541?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352578924001541?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39206109

Fields of Study

Chemotherapy-related skin toxicityCancer Treatment and PharmacologyDrug-Induced Adverse Reactions03 medical and health sciences0302 clinical medicine

Keywords

PaclitaxelMedicineEndometrial cancerOvarian cancerInternal medicineOncologyRetrospective cohort studyNab-paclitaxelChemotherapyCancerAllergic reactionsRG1-991Case Reports and Case SeriesNeoplasms. Tumors. Oncology. Including cancer and carcinogensGynecology and obstetricsRC254-282